### **Overview** **Nitta Gelatin India Limited (NGIL)**, established in 1975 as a joint venture between the Kerala State Industrial Development Corporation Ltd. and Japan-based **Nitta Gelatin Inc.**, is a leading Indian manufacturer of high-quality gelatin, collagen peptides, ossein, and dicalcium phosphate (DCP). The company operates two core divisions—**Ossein** and **Gelatin**—in Kerala, with a strong domestic and international footprint. Over 50% of its output is exported to more than 30 countries, including the USA, Canada, Japan, South Korea, and EU nations. NGIL serves highly regulated markets such as **pharmaceuticals, nutraceuticals, food, feed, and cosmetics**, leveraging advanced technology and a vertically integrated supply chain. It is the only Indian producer of **capsule-grade gelatin** using proprietary blends of bone and hide gelatin, ensuring cost-efficiency and superior quality. --- ### **Core Business Segments & Product Portfolio** #### **1. Gelatin Production** - **Specialization**: Over 95% of the company’s gelatin capacity is dedicated to **capsule-grade gelatin**, meeting stringent international pharmacopeia standards (USP, EP, JP). - **Technology Edge**: NGIL utilizes **advanced blending technology** combining bone and hide sources, enhancing functionality and reducing costs. - **Capacity Expansion**: A planned **1,500 MT expansion** focused on **bovine hide gelatin** is underway, reinforcing its strategic shift toward alternative, cost-effective raw materials. - **Plant Performance**: The gelatin plant operated at **full capacity in FY2023–24 and FY2024–25**, driven by robust demand from pharmaceutical and nutraceutical sectors. #### **2. Collagen Peptides** - **Wellnex Brand**: NGIL’s flagship line of **scientifically validated, high-functional collagen peptides**, targeting wellness, beauty-from-within, joint health, and diabetes management. - **Wellnex Di-Peptide**: A breakthrough product containing **30x more bioactive dipeptides (PO/OG)** than standard collagen peptides, offering enhanced efficacy at lower dosages for skin, joints, and wound healing. - **Wellnex Pro-D**: Clinically studied for **diabetes management**, shown to reduce HbA1c and fasting blood glucose levels—positioning NGIL at the forefront of functional health innovation. - **Market Position**: The first supplier globally to identify and utilize **PO and OG dipeptides**, creating significant scientific differentiation. #### **3. Other Products** - **Ossein & Limed Ossein**: Used in animal feed and industrial applications; exported consistently despite logistical challenges. - **Dicalcium Phosphate (DCP)**: Benefited from rising poultry consumption in India and increased export prices of mineral phosphates, boosting revenues. - **Chitosan**: Produced for various industrial uses, expanding portfolio diversification. --- ### **Strategic Market Developments** #### **Global Market Tailwinds** - The **global gelatin capsule market** was valued at **USD 5.85 billion in 2024** and is projected to reach **USD 8.08 billion by 2030** (CAGR: 5.5%), driven by growth in **softgel capsules**. - The **collagen peptide market** is expected to grow at a **CAGR of over 7%**, fueled by aging populations, preventive healthcare trends, and rising demand in nutricosmetics and sports nutrition. - India’s emergence as a **nutraceutical and wellness hub** is accelerating domestic and export demand for gelatin and collagen peptides. #### **Sales & Distribution Channels** - **B2C via E-commerce**: The **Gelixer brand** (Gelixer Classic, Gelixer Beauty) is available on **Amazon and Flipkart**, enabling broad consumer reach, especially in semi-urban and rural areas. - **B2B Bulk Supply**: Strong partnerships with brands across India and overseas; increasing penetration in functional food, beverages, and clinical nutrition. - **Export Markets**: The U.S. remains a key market, but NGIL is actively diversifying into **Europe, UK, Turkey, Middle East, Southeast Asia, and Africa** to mitigate regional overreliance. --- ### **Operational & Supply Chain Strategy** #### **Raw Material Sourcing & Innovation** - **Domestic Challenges**: Declining quality of local crushed bones has prompted imports of premium **Gelbone** from France, Canada, and New Zealand. - **Imports**: Contracted **2,500 MT** of Gelbone; ongoing negotiations with Canadian suppliers. Advocacy underway for relaxed import norms from BSE-undetermined countries under OIE standards. - **Alternative Sources**: Pioneering use of **bovine hide**, a more cost-effective and sustainable raw material, due to declining demand from leather/automotive sectors. - **Pilot Initiative**: Collaboration with bone suppliers to develop **high-quality degreased crushed bone (DCB)** to improve consistency and reduce impurities. #### **Supply Chain Resilience** - **Red Sea Crisis Impact**: Transit times to Europe and North America extended to **60–75 days**, increasing inventory costs. - **Response**: Enhanced **demand forecasting**, inventory buildup, and agile manufacturing to maintain supply continuity. - **Cost Optimization**: Stable raw material sourcing and improved production efficiency are helping balance input and end-product pricing. --- ### **Research, Development & Innovation** #### **R&D Focus** - R&D centers recognized by **India’s DSIR**, focusing on: - Novel collagen-based products for wellness, beauty, immunity, and cognitive health. - Improving bioavailability, shelf life, and energy efficiency in production. - Exploring **marine and aqua-based collagen** to diversify feedstock and meet market innovation needs. #### **Product Diversification** - Developing new delivery formats: **powders, ready-to-drink beverages, mouth-melting tablets, gummies**. - Formulating **pet nutritional products** using human-grade collagen peptides. - Expanding into **cross-category applications** such as clinical nutrition and functional treats. --- ### **Financial & Competitive Position** #### **Revenue Drivers** - **Gelatin Segment**: Full capacity utilization due to strong pharma/nutraceutical demand. - **Collagen Peptides**: Sales growth driven by new customer acquisition, B2C e-commerce, and competitively priced inputs. - **Feed & Fertilizer Business**: Increased DCP revenues due to high poultry feed demand and reduced imports. #### **Margin Pressures** - Narrowing price gap between **gelatin and collagen peptides**. - Declining bovine hide collagen prices and entry of **raw material suppliers into peptide processing**, increasing competition. - Fish collagen market saturation in Asia post-R&D boom. --- ### **Future Outlook & Strategic Roadmap (as of Nov 2025)** - **Capacity Expansion**: Completion of the **1,500 MT bovine hide gelatin expansion** remains a priority to strengthen margins and supply security. - **Collagen Growth Plan**: Full utilization of expanded **1,000 MT collagen peptide production capacity** (up from 450 MT) is expected to drive export-led growth. - **Innovation Pipeline**: Ongoing development of **multi-benefit, clinically supported peptides** for diabetes, joint health, and anti-aging applications. - **Sustainability & Compliance**: Focus on improving process efficiency, reducing waste, and aligning with global ESG benchmarks. - **Geographic Diversification**: De-risking reliance on the U.S. by expanding in EU, Middle East, and African markets. --- ### **Key Competitive Advantages** 1. **Technology leadership** in capsule-grade gelatin in India. 2. **Scientific differentiation** in collagen peptides via **PO/OG dipeptide identification**. 3. **Cost-efficient hybrid raw material strategy** (bone + hide). 4. **Strong compliance** with global regulatory standards. 5. **Dual B2B and B2C channels**, with growing direct-to-consumer presence. 6. **Backed by a global parent (Nitta Gelatin Group)** with R&D and market access synergies. --- ### **Challenges** - Regulatory delays in approving new raw material sources. - Supply chain disruptions due to geopolitical conflicts (Red Sea, Suez traffic decline). - Pricing competition from new market entrants, especially hide-based suppliers. - Economic slowdown in Southeast Asia limiting regional growth. ---